China: Unusual Remedies a Feature of Mofcom’s 6th Conditional Clearance Decision

Last Updated: 23 August 2010
Article by Hannah C. L. Ha and Gerry P. O'Brien

China's Ministry of Commerce (Mofcom) has approved the proposed acquisition by Swiss pharmaceutical company Novartis AG ("Novartis") of world-leading eye care company Alcon Inc. ("Alcon"), subject to conditions.

The decision, announced on 13 August 2010, is Mofcom's first published merger control decision in almost 10 months, and the sixth time that Mofcom has included conditions in its approval of an M&A transaction under China's Anti-Monopoly Law. Notably, all of these decisions have applied to transactions between foreign multinationals (and the single prohibition decision that has been announced concerned a foreign takeover of a domestic Chinese business).

The latest decision has attracted particular scrutiny because of the unusual nature of the conditions attached to Mofcom's approval. In this legal update, we examine the decision and identify the key learnings that the business sector can draw from it.

Background: The Novartis/Alcon transaction

Novartis purchased a 25% stake in Alcon during 2008, and subsequently announced that it intended to purchase a controlling stake in the company.

One of the key commercial drivers of the deal was the incentive of combining Alcon's world-leadership in ophthalmic surgery products with Ciba Vision – a Novartis subsidiary specialising in contact lenses and related products. According to the Novartis' takeover plan communicated to Mofcom, Alcon would be established as a new Novartis eyecare division, and Novartis would cease some minor overlapping operations in the relevant sector.

Originally published August 20, 2010

Keywords: antitrust agencies, clearance decision, Mofcom, Novartis, China

The proposed transaction was required to be notified to antitrust agencies in several jurisdictions, including the US, Canada, EU, Singapore and China. Singapore's Competition Commission issued an unconditional clearance decision in relation to the deal in May this year, while the European Commission and Canada's Competition Bureau cleared the deal in early August after Novartis offered to divest its eye care businesses to address competition issues identified in those jurisdictions. The US regulators reached a settlement agreement with Novartis just a few days after Mofcom's decision was published, with Novartis agreeing to sell off a cataracts drug to a third party under that agreement.

Notification to Mofcom and identified competition concern

According to Mofcom's decision notice, Novartis formally notified the proposed transaction in China on 20 April 2010.

After preliminary review, Mofcom determined that the transaction may have the effects of eliminating or restricting competition in relation to two product markets in China:

i. The product market relating to ophthalmic anti-inflammatory and anti-infective compounds (a drug that can be used for the treatment of eye inflammation or infections, especially after ophthalmic surgery, and hereafter referred to for convenience as "medicated eye-care products"); and

ii. The product market relating to contact lens care products,

and thus decided to initiate further review on 17 May 2010. Overall, Mofcom's formal review process in relation to the transaction took just under four months.

According to the decision notice, Mofcom's concerns about the impact of the proposed transaction on these product markets were as follows:

i. Medicated eye-care products

Mofcom determined that the combined market share of Novartis and Alcon in the product market relating to medicated eye-care products would, post-completion, exceed 55% globally and 60% in China. It is notable, however, that the China market share figure was based on Mofcom's determination that Alcon's current China market share was over 60% - while Novartis' share of this China market was less than 1%.

Although Novartis advised Mofcom of its decision to withdraw its existing operations in the global and Chinese market for this type of product, Mofcom appears to have been concerned about the prospect of Novartis seeking to strengthen its position in the relevant market in China by reversing this decision after completion of its acquisition of Alcon.

ii. Contact lens care products

Mofcom determined that the combined market share of Novartis and Alcon in this product market would reach nearly 60% post-completion, which was much greater than the global market share of the parties' main competitors. Additionally, Mofcom determined that the parties would have a market share in China of nearly 20%, making it the second largest player by market share (behind Taiwanese company Haichang Contact Lens Co. Ltd. ("Haichang"), which has a market share in China exceeding 30%).

Mofcom also noted that a Novartis subsidiary had in place a strategic partnership agreement with Haichang, under which Haichang was the exclusive distributor in China of relevant contact lens care products produced by the Novartis subsidiary. Mofcom expressed concern that coordination between Haichang and Novartis/Alcon post-completion could also produce restrictive effects in the market.

Negotiation and determination of remedies

It is clear from the decision notice that Mofcom and Novartis engaged in extended negotiation of remedies with Mofcom to allay the regulator's concerns about the impact of the transaction on relevant product markets in China. Indeed, the notice states that the finalised remedies were reached by consensus. Those remedies are as follows:

1. In order to address Mofcom's concerns about the impact of the transaction in respect of the product market relating to medicated eye-care products, Novartis is required by the end of 2010 to cease its own sales of such products in China. The restriction on such sales will last for a period of five years from the date of Mofcom's decision.

2. In order to address Mofcom's concerns about the impact of the transaction in respect of the product market relating to contact lens care products, Novartis must terminate its strategic partnership agreement with Haichang within 12 months of Mofcom's decision.

In accordance with interim rules that Mofcom published in July regarding the implementation process for merger control remedies, Novartis is required to report to Mofcom regarding its fulfilment of the above conditions, and to appoint a trustee to conduct supervision in respect of the same.

Mofcom's unusual and under-explained remedies

Mofcom's decision to require that Novartis withdraw its medicated eye-care products from the China market may be seen as unusual given Novartis's tiny share of the relevant market in China. Although Novartis had already communicated to Mofcom its intention to effect such withdrawal, it is difficult to ascertain (and certainly the decision notice does not explain) why Mofcom would identify a need to make this a binding commitment for a five year period given that Novartis' existing market share was minor enough to suggest that the merged entity would not be able to materially increase its market power if Novartis continued with its participation in the market in conjunction with Alcon.

Even if Mofcom had legitimate concerns regarding this issue, a more favourable remedy (in terms of benefiting consumers by increasing market choice) may have been to order Novartis to sell its business in the market rather than withdraw it altogether. Again, while there may have been sound reasons for not pursuing this remedy, they are not explained in Mofcom's decision notice.

Mofcom's decision to require that Novartis terminate its strategic partnership agreement with Haichang is perhaps more understandable, given its concern about the potential for ongoing market coordination between two significant players in relation to the supply of contact lens care products in the region. However, while few antitrust analysts would question the validity of Mofcom exploring these concerns during its review process, the decision notice provides little evidence of intensive investigation of the issue. The notice simply states that the relevant agreement may lead to coordination on pricing, sales volumes, and sales regions - and thereby restrict competition - without providing the kind of considered analysis of the actual likelihood and actual market impact of such coordination that is commonplace in the merger review decisions of regulators in more mature competition law jurisdictions.


Notwithstanding the unusual and under-explained remedies imposed by Mofcom in relation to this transaction, there are some encouraging elements to the decision for the wider business sector. In particular, many business operators will welcome the fact that Mofcom continues to be keen to negotiate remedies with parties to transactions that it identifies as raising competition concerns, and is flexible enough to accept proposed remedies that address such concerns even if they are more favourable to the transaction parties than alternatives which could be construed as beneficial to consumers and the broader competitive process of the market.

However, many observers of China's antitrust regime will also have noted the irony in the fact that this decision was announced just a day after Mofcom held a news conference in which it defended its treatment of foreign businesses under the merger control system - notwithstanding that only foreign companies had been subject to remedies in merger clearance decisions until that point. Mofcom's latest merger decision continues that record, and may lead to further questions from foreign commentators regarding whether political pressure is restricting Mofcom's ability to subject domestic transactions to the same level of scrutiny as foreign deals.

Copyright 2010. JSM, Mayer Brown International LLP and/or Mayer Brown LLP. All rights reserved. Mayer Brown is a global legal services organization comprising legal practices that are separate entities ("Mayer Brown Practices"). The Mayer Brown Practices are: JSM, a Hong Kong partnership, and its associated entities in Asia; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales; and Mayer Brown LLP, a limited liability partnership established in the United States. The Mayer Brown Practices are known as Mayer Brown JSM in Asia.

This article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein. Please also read the JSM legal publications Disclaimer.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.